<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953834</url>
  </required_header>
  <id_info>
    <org_study_id>2016P001769</org_study_id>
    <nct_id>NCT02953834</nct_id>
  </id_info>
  <brief_title>Kisspeptin Influence on Glucose Homeostasis</brief_title>
  <official_title>Kisspeptin Influence on Glucose Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephanie B. Seminara, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines how a naturally occurring peptide called kisspeptin might regulate blood&#xD;
      sugar and insulin levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average difference in area under the curve of insulin in response to a mixed meal tolerance test</measure>
    <time_frame>4 hours</time_frame>
    <description>Compares difference on and off kisspeptin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average difference in area under the curve of glucose in response to a mixed meal tolerance test</measure>
    <time_frame>4 hours</time_frame>
    <description>Compares difference on and off kisspeptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average difference in area under the curve of glucagon-like peptide 1 in response to a mixed meal tolerance test</measure>
    <time_frame>4 hours</time_frame>
    <description>Compares difference on and off kisspeptin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">413</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Kisspeptin and Insulin Resistance Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Insulin Resistance Test</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous administration of IV fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kisspeptin 112-121</intervention_name>
    <description>Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours</description>
    <arm_group_label>Kisspeptin and Insulin Resistance Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insulin Resistance Test</intervention_name>
    <description>Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar</description>
    <arm_group_label>Kisspeptin and Insulin Resistance Test</arm_group_label>
    <arm_group_label>Placebo and Insulin Resistance Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Receive intravenous fluids for up to 16 hours that do not contain any study drug</description>
    <arm_group_label>Placebo and Insulin Resistance Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:&#xD;
&#xD;
        History:&#xD;
&#xD;
          -  normal pubertal development&#xD;
&#xD;
          -  stable weight for previous three months&#xD;
&#xD;
          -  no active illicit drug use,&#xD;
&#xD;
          -  no history of a medication reaction requiring emergency medical care,&#xD;
&#xD;
          -  no difficulty with blood draws.&#xD;
&#xD;
        Physical examination:&#xD;
&#xD;
        â€¢ systolic BP &lt; 140 mm Hg, diastolic &lt; 90 mm Hg,&#xD;
&#xD;
        Laboratory studies: (per MGH reference ranges)&#xD;
&#xD;
          -  normal hemoglobin, unless hypogonadal then no lower than 0.5 gm/dL below the lower&#xD;
             limit of the reference range for normal women (as men and women with hypogonadism have&#xD;
             lower hemoglobin levels off of treatment)&#xD;
&#xD;
          -  hemoglobin A1C &lt; 6.5%&#xD;
&#xD;
          -  BUN, creatinine not elevated&#xD;
&#xD;
          -  AST, ALT &lt; 3x upper limit of normal&#xD;
&#xD;
          -  negative serum pregnancy test (for all women)&#xD;
&#xD;
          -  no hyperlipidemia by fasting lipid panel&#xD;
&#xD;
        Additional Criteria by Study Population&#xD;
&#xD;
        Healthy Men:&#xD;
&#xD;
          -  normal body mass index (BMI between 18.5-25)&#xD;
&#xD;
          -  no history of chronic disease, except well controlled thyroid disease&#xD;
&#xD;
          -  no recent use of prescription medications which interfere with metabolism or&#xD;
             reproduction. Use of levothyroxine or seasonal allergy medications is acceptable.&#xD;
&#xD;
          -  no history of diabetes in a first degree relative.&#xD;
&#xD;
        Healthy Women:&#xD;
&#xD;
          -  normal body mass index (BMI between 18.5-25)&#xD;
&#xD;
          -  no history of chronic disease, except well controlled thyroid disease,&#xD;
&#xD;
          -  no recent use of prescription medications which interfere with metabolism or&#xD;
             reproduction. Use of levothyroxine or seasonal allergy medications is acceptable.&#xD;
&#xD;
          -  no history of diabetes in a first degree relative,&#xD;
&#xD;
          -  no use of contraceptive pills, patches or vaginal rings within last 4 weeks.&#xD;
&#xD;
          -  regular menstrual cycles&#xD;
&#xD;
        Postmenopausal Women:&#xD;
&#xD;
          -  body mass index (BMI between 18.5-30)&#xD;
&#xD;
          -  no history of chronic disease except thyroid disease, and osteoporosis,&#xD;
&#xD;
          -  no recent use of prescription medications which interfere with metabolism or&#xD;
             reproduction. Use of levothyroxine, osteoporosis medications or seasonal allergy&#xD;
             medications is acceptable,&#xD;
&#xD;
          -  no history of diabetes in a first degree relative,&#xD;
&#xD;
          -  normal activate protein C resistance screen,&#xD;
&#xD;
          -  if applicable, able to undergo appropriate washout from hormone therapy.&#xD;
&#xD;
        Men and Women with Impaired Glucose Tolerance (IGT):&#xD;
&#xD;
          -  diagnosis of impaired glucose tolerance by oral glucose tolerance test,&#xD;
&#xD;
          -  all medical conditions well-controlled.&#xD;
&#xD;
        Men and Women with Hypogonadism&#xD;
&#xD;
          -  diagnosis of hypogonadism,&#xD;
&#xD;
          -  all other medical conditions well-controlled,&#xD;
&#xD;
          -  if applicable, able to undergo appropriate washout from hormone therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Lippincott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Lippincott, MD</last_name>
    <phone>617-726-8434</phone>
    <email>mlippincott@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Lippincott, MD</last_name>
      <phone>617-726-8434</phone>
      <email>mlippincott@partners.org</email>
    </contact>
    <investigator>
      <last_name>Margaret Lippincott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Seminara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Sciences Center</investigator_title>
  </responsible_party>
  <keyword>insulin regulation in pregnancy</keyword>
  <keyword>kisspeptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After primary results are published, the authors will provide individuals participant data upon request as long as it does not conflict with state or Institutional regulations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

